|  | | FDG-PET lesions at treatment discontinuation | |  |
| --- | --- | --- | --- | --- |
| Characteristic | Overall, N = 1401 | PET- lesions, N = 1091 | PET+ lesions, N = 311 | p-value2 |
| Gender |  |  |  | 0.082 |
| Male | 85 (61%) | 62 (57%) | 23 (74%) |  |
| Female | 55 (39%) | 47 (43%) | 8 (26%) |  |
| Age | 69 (58, 74) | 69 (58, 74) | 69 (58, 76) | 0.695 |
| Melanoma diagnosis |  |  |  | 0.228 |
| Cutaneous | 125 (89%) | 97 (89%) | 28 (90%) |  |
| Mucosal | 1 (0.7%) | 0 (0%) | 1 (3.2%) |  |
| Unknown primary | 14 (10%) | 12 (11%) | 2 (6.5%) |  |
| Performance status |  |  |  | 0.052 |
| PS 0 | 101 (72%) | 79 (72%) | 22 (71%) |  |
| PS 1 | 35 (25%) | 29 (27%) | 6 (19%) |  |
| PS 2 | 4 (2.9%) | 1 (0.9%) | 3 (9.7%) |  |
| LDH |  |  |  | 0.169 |
| <ULN | 110 (80%) | 88 (82%) | 22 (71%) |  |
| >ULN | 28 (20%) | 19 (18%) | 9 (29%) |  |
| Unknown | 2 | 2 | 0 |  |
| BRAF status |  |  |  | 0.450 |
| Wild-type | 79 (56%) | 59 (54%) | 20 (65%) |  |
| Mutated | 57 (41%) | 47 (43%) | 10 (32%) |  |
| Unknown | 4 (2.9%) | 3 (2.8%) | 1 (3.2%) |  |
| Disease Stage |  |  |  | 0.917 |
| M1a | 26 (19%) | 21 (19%) | 5 (16%) |  |
| M1b | 38 (27%) | 30 (28%) | 8 (26%) |  |
| M1c | 62 (44%) | 48 (44%) | 14 (45%) |  |
| M1d | 14 (10%) | 10 (9.2%) | 4 (13%) |  |
| Immunotherapy |  |  |  | 0.179 |
| Anti-PD-1 | 104 (74%) | 78 (72%) | 26 (84%) |  |
| Ipilimumab+Nivolumab | 26 (19%) | 21 (19%) | 5 (16%) |  |
| Anti-PD-1+experimental | 10 (7.1%) | 10 (9.2%) | 0 (0%) |  |
| Treatment duration in months ± SD | 7.8 (3.9, 11.6) | 8.4 (4.3, 12.2) | 5.5 (2.4, 10.3) | 0.082 |
| High dose immunosuppressants |  |  |  | 0.066 |
| 0 | 115 (82%) | 93 (85%) | 22 (71%) |  |
| 1 | 25 (18%) | 16 (15%) | 9 (29%) |  |
| First line treatment | 123 (88%) | 98 (90%) | 25 (81%) | 0.210 |
| group |  |  |  | 0.002 \*\* |
| elective | 92 (66%) | 79 (72%) | 13 (42%) |  |
| toxicity | 48 (34%) | 30 (28%) | 18 (58%) |  |
| 1n (%); Median (IQR) | | | | |
| 2\*p<0.05; \*\*p<0.01; \*\*\*p<0.001 | | | | |